Peptide Half-Life Chart: The Complete Reference Guide for Researchers

Why Peptide Half-Life Matters for Research Protocols

When researchers design peptide study protocols, one variable shapes every decision more than almost any other: half-life. A peptide's half-life determines how long the compound remains biologically active in a given system, directly influencing dosing frequency, stability requirements, and overall experimental design.

This complete reference guide breaks down the known and estimated half-lives of the most widely studied research peptides — all in one place. Whether you are new to peptide research or refining an advanced protocol, this chart is the resource you have been looking for.

What Is Peptide Half-Life?

In pharmacokinetics, half-life (t½) refers to the time it takes for the concentration of a compound to reduce by 50% in a biological system. For peptides, this is especially important because these short-chain amino acid sequences are inherently susceptible to enzymatic degradation by peptidases and proteases present in plasma and tissue.

Several factors influence a peptide's half-life, including:

• Route of administration — subcutaneous, intravenous, intranasal, or oral delivery each produce different absorption and degradation profiles
• Amino acid sequence — the presence of D-amino acids or specific protective sequences can dramatically extend stability
• Molecular modifications — PEGylation, DAC (Drug Affinity Complex) conjugation, and acetylation can extend duration significantly
• Temperature and storage conditions — improper storage accelerates degradation before administration

The Complete Peptide Half-Life Reference Chart

The following data is compiled from published preclinical studies, pharmacokinetic analyses, and manufacturer-reported research data. All values represent estimates in animal or in-vitro models unless otherwise noted.

Healing and Recovery Peptides

• BPC-157 — Estimated half-life: 4 hours (subcutaneous); research suggests stable systemic presence for approximately 6-8 hours post-administration. Bpc 157
• TB-500 (Thymosin Beta-4 fragment) — Estimated half-life: varies widely; studies indicate a longer duration of action than BPC-157 owing to its 43-amino-acid structure, with some models suggesting activity windows of 24+ hours
• GHK-Cu (Copper Peptide) — Estimated half-life: approximately 30-60 minutes in plasma; topical preparations exhibit localized persistence beyond this window

Growth Hormone Secretagogues

• CJC-1295 (without DAC) — Estimated half-life: 30 minutes; designed to mimic a natural GHRH pulse and clear rapidly from the system
• CJC-1295 (with DAC) — Estimated half-life: 6-8 days; the Drug Affinity Complex modification binds albumin, dramatically extending its presence and creating a sustained GH release pattern in research models
• Ipamorelin — Estimated half-life: approximately 2 hours; research suggests selective GH release without significant cortisol or prolactin elevation in animal models
• Sermorelin — Estimated half-life: 10-20 minutes; one of the shortest-acting GHRH analogs, noted for its physiological pulsatile action profile
• GHRP-6 — Estimated half-life: approximately 15-60 minutes depending on model; studies indicate ghrelin-mediated receptor activation
• Hexarelin — Estimated half-life: approximately 70 minutes in plasma pharmacokinetic models
• MK-677 (Ibutamoren) — Estimated half-life: 24 hours; notable for oral bioavailability and prolonged GH secretagogue activity

Neuropeptides and Cognitive Research Peptides

• Semax — Estimated half-life: approximately 20-30 minutes (intranasal); despite rapid clearance, neurological effects in animal models appear to extend well beyond the plasma half-life window
• Selank — Estimated half-life: approximately 3-5 minutes in plasma; often administered intranasally where mucosal absorption may extend effective duration
• DSIP (Delta Sleep-Inducing Peptide) — Estimated half-life: approximately 30 minutes; research in animal models explores its potential role in sleep architecture regulation
• Dihexa — Estimated half-life: estimated at several hours orally; preclinical models suggest pronounced nootropic-adjacent activity relative to its molecular weight

Longevity and Immunomodulatory Peptides

• Epithalon (Epitalon) — Estimated half-life: short plasma clearance (minutes to hours); animal studies suggest downstream effects on telomerase activity persist beyond the compound's presence
• Thymosin Alpha-1 (Ta1) — Estimated half-life: approximately 2 hours; research indicates immunomodulatory signaling in preclinical models related to T-cell activity
• LL-37 — Estimated half-life: minutes in plasma due to rapid protease cleavage; antimicrobial peptide research focuses heavily on delivery formulations to extend stability

Key Takeaways for Protocol Design

Understanding half-life data allows researchers to think critically about administration timing, compound pairing, and expected activity windows. A few principles worth noting:

• Shorter half-life peptides like Sermorelin and Selank require more frequent administration windows to maintain consistent tissue-level exposure in study models
• Modified peptides like CJC-1295 with DAC demonstrate how structural engineering can extend duration by several orders of magnitude
• Half-life in plasma does not always predict duration of downstream biological effect — downstream receptor signaling, gene expression changes, and secondary messenger cascades may persist far longer than the peptide itself

Storage Conditions and Stability Considerations

Half-life values assume properly synthesized and stored research-grade peptides. Degradation can begin before administration if storage protocols are not followed. Research-grade peptides from Maxx Laboratories are lyophilized (freeze-dried) to maximize shelf stability and should be stored at -20°C in sealed vials until reconstitution. Peptide Storage Guide

Once reconstituted with bacteriostatic water, most peptides should be kept at 4°C and used within 28-30 days. Repeated freeze-thaw cycles should be avoided, as each cycle contributes to degradation and reduced purity.

Maxx Labs: Research-Grade Peptides with Verified Purity

Every peptide offered through Maxx Laboratories undergoes third-party HPLC testing to verify sequence integrity and purity above 98%. Accurate half-life data is only meaningful when the compound being studied meets rigorous quality standards from the start. Quality Testing

Explore our full catalog of research-grade peptides and download the corresponding Certificates of Analysis for each batch at maxxlaboratories.com.